Agios Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AGIO research report →
Range $32 – $55
Price Chart
About the company
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias.
- CEO
- Brian Goff
- IPO
- 2013
- Employees
- 540
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on AGIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.65B
- P/E
- -4.55
- Fwd P/E
- 99.99
- PEG
- -0.52
- P/S
- 12.21
- P/B
- 1.75
- EV/EBITDA
- -4.28
- Div Yield
- 0.00%
- Gross Margin
- 91.94%
- Op Margin
- -297.72%
- Net Margin
- -264.76%
- ROE
- -34.63%
- ROIC
- -41.56%
Latest fiscal year · YoY change
- Revenue
- $54.03M+48.0%
- Gross Profit
- $42.51M+31.5%
- Op Income
- $-472,132,000
- Net Income
- $-412,781,000-161.3%
- EPS
- $-7.12-160.0%
- OCF Growth
- +4.3%
- FCF Growth
- +3.6%
- 52W High
- $44.09
- 52W Low
- $23.00
- 50D MA
- $32.76
- 200D MA
- $31.88
- Beta
- 0.62
- RSI (14)
- 38
- Avg Volume
- 1.06M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Agios posted record third-quarter mitapivat revenue driven by AQVESME’s thalassemia launch, while the company pushed its sickle cell filing timeline out by three months and kept its 2028 non-GAAP profitability target.· November 5, 2026
- Record quarter: total net revenue was $55.4 million, more than 4x the year-ago quarter; U.S. net revenue was $48.7 million.
- AQVESME/thalassemia launch continued to broaden, with 177 completed start forms in the quarter and 619 cumulative since launch; management said that is roughly 15% of its target launch population.
- The FDA asked for more information on whether a REMS is needed for mitapivat in sickle cell disease, extending review to February 1, 2027; management still expects approval is possible and says it is launch-ready.
- Cash ended at $907 million, and management reiterated a target of non-GAAP profitability in 2028.
- Pipeline updates included planned phase 3 initiation for AG-236 in polycythemia vera by year end, phase 3 for cevidoplenib in ITP in the first half of 2028, and PKU data for AG-181 before year-end.
Agios reported third-quarter total net revenue of $55.4 million, versus $12.9 million in the third quarter of 2025. U.S. net revenue was $48.7 million and ex-U.S. net revenue was $6.6 million. Cost of sales was $2.5 million versus $1.7 million a year ago. R&D expense was $73.5 million, down from $86.8 million, while SG&A was $56.5 million, up from $41.3 million. Net loss was $65 million versus a net loss of $103 million last year. The company ended the quarter with $907 million in cash equivalents and marketable securities. Management said full-year 2026 operating expenses are expected to be approximately flat versus 2025, excluding a $25 million upfront payment for cevidoplenib (recognized in Q2) and an approximately $11 million one-time headcount-reduction expense in Q4. Forward, the company said the FDA’s major amendment on the sickle cell sNDA extends the review timeline by three months to February 1, 2027; management continues to target non-GAAP profitability in 2028.
Brian Goff framed the quarter as proof that Agios is becoming a focused rare hematology company with a scalable commercial base. He highlighted record revenue, strong AQVESME execution, and the company’s preparedness for a potential sickle cell launch, while stressing that the business is being rightsized to concentrate capital on the highest-value opportunities. His tone was confident but measured, especially around the FDA delay, which he described as timing-related rather than a change in the commercial opportunity.
Cecilia Jones walked through the quarter’s financial performance, noting $55.4 million in total mitapivat revenue, $73.5 million in R&D, $56.5 million in SG&A, and a $65 million net loss. She emphasized the balance sheet, citing $907 million in cash equivalents and marketable securities, and said this supports AQVESME, a potential sickle cell launch, and the pipeline. She also said operating expenses for full-year 2026 should be roughly flat versus 2025 excluding the cevidoplenib upfront payment and the Q4 headcount-reduction charge, and that the cost savings from cutting more than 100 roles, or more than 35% of R&D headcount versus 2025, should mostly show up in 2027.
Analysts focused on three main issues: the FDA’s REMS-related delay in sickle cell, how to think about competitive positioning and cross-trial comparisons, and the impact of the R&D restructuring on future spending and profitability. Management said no other FDA issues beyond the REMS discussion had been raised, described the review as a timing shift rather than a change in the opportunity, and said the team is launch-ready regardless of scenario. On commercialization, it said the sickle cell launch would target about 25,000 actively treated or treatment-needing patients and would be supported by the same commercial infrastructure used in thalassemia. On the pipeline, management said AG-236’s phase 2 will focus on dose-finding before moving toward phase 3, while PKU remains an optional asset pending proof-of-mechanism data.
The bull case is that Agios is already demonstrating a scalable commercial launch in thalassemia, with revenue growth, broadening demand, and about 75% persistence at roughly six months. Management also sounded confident that the sickle cell delay does not alter the core opportunity, and it pointed to continued follow-up data suggesting durable hemoglobin responses plus possible kidney and cardiac benefits. The company’s $907 million cash balance and planned cost reductions support the idea that it can fund launches and pipeline progress while moving toward 2028 profitability.
The main risks are regulatory and execution-related: the FDA’s REMS request pushed the sickle cell timeline out by three months, and management would not specify what label or REMS outcome will look like. There is also reliance on continued uptake and persistence in thalassemia to justify the launch trajectory, and the company declined to split prescription data by patient segment. Finally, the operating model is being restructured, with more than 100 R&D roles being eliminated and a one-time Q4 charge expected, which underscores that the company is still working through cost discipline rather than operating from established profitability.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.6%
- Shares Outstanding
- 59.81M
- Float Shares
- 58.36M
of shares held by institutions
252 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for AGIO, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | Aug 20, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Mar 3, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Dec 11, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Apr 17, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jan 29, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Jan 24, 24 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 6.23M | ▼ 226.80K |
| Farallon Capital Management, L.L.C. | 5.92M | ▲ 233.40K |
| Vanguard Group Inc | 5.59M | ▼ 10.52K |
| Morgan Stanley | 3.44M | ▲ 2.47M |
| Lynx1 Capital Management LP | 3.41M | ▲ 797.37K |
| State Street Corp | 3.26M | ▼ 268.98K |
| D. E. Shaw & Co., Inc. | 3.11M | ▲ 425.84K |
| Vanguard Portfolio Management LLC | 2.85M | ▼ 47.99K |
| Vanguard Capital Management LLC | 2.69M | ▲ 6.01K |
| Armistice Capital, LLC | 2.40M | ▼ 316.00K |
| Nomura Asset Management International Inc. | 2.11M | ▲ 616.37K |
| Assenagon Asset Management S.A. | 1.89M | ▲ 1.78M |
Held by 375 ETFs
Biggest fund positions in AGIO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 26, 26 | Gheuens Sarah | other | 7,866 |
| Oct 26, 26 | Gheuens Sarah | sell | 7,866 |
| Oct 26, 26 | Gheuens Sarah | other | 7,866 |
| Oct 21, 26 | Gheuens Sarah | other | 1,489 |
| Oct 22, 26 | Gheuens Sarah | other | 500 |
| Oct 21, 26 | Gheuens Sarah | sell | 1,489 |
| Oct 22, 26 | Gheuens Sarah | sell | 500 |
| Oct 21, 26 | Gheuens Sarah | other | 1,489 |
| Oct 22, 26 | Gheuens Sarah | other | 500 |
| Aug 4, 26 | Gheuens Sarah | sell | 30,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AGIO coverage
Recent articles, reports, and earnings notes.
No research on AGIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AGIO report →Agios Pharmaceuticals, Inc. (AGIO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 7
What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call
marketbeat.com · Nov 5
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates
zacks.com · Nov 5
Agios Reports Third Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Nov 5
Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026
globenewswire.com · Nov 4
Agios: News On Sickle Cell Approval Decision Delay May Not Derail Bull Thesis (Upgrade)
seekingalpha.com · Oct 30
Agios Announces New PDUFA Goal Date of February 1, 2027, for Mitapivat Sickle Cell Disease sNDA; Company Is Launch-Ready and in Labeling Discussions with FDA
globenewswire.com · Oct 30
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
zacks.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.